@KUcancercenter profile picture
KU Cancer Center @KUcancercenter

We are transforming cancer research and clinical care by linking our innovative approach to drug discovery, delivery and development to our patient care program

Joined September 2009
  • Tweets 11,912
  • Following 1,698
  • Followers 6,102
3,132 Photos and videos
A new "Triple Threat" CAR T-cell therapy developed at KU Cancer Center is designed to attack three cancer targets at once, potentially overcoming a major challenge in treating blood cancers. Ramesh Balusu, PhD, scientific director of the Midwest Stem Cell Therapy Center, recently sat down with @SocietyofHemOnc to discuss early results from a phase 1 clinical trial and the benefits of engineering T-cells on-site. youtube.com/watch?v=fWnGm-Xq…

Tri-specifc CAR-T shows early activity in B-cell malignancies

In this SOHO Insider interview from the AACR Annual Meeting 2026, R...

youtube.com
1
2
5
345
On the latest episode of the Bench to Bedside podcast, Dr. Tara Lin and Dr. Jesus Gonzalez Lugo share an update on #MyeloMATCH, a first-of-its-kind national clinical trial designed to bring precision medicine to patients with #AML. Tune in today: bit.ly/3Jet1Uu
Three people sit around a table in a recording studio, with microphones, papers, and water bottles on the table.

ALT Three people sit around a table in a recording studio, with microphones, papers, and water bottles on the table.
2
8
517
Teaching Kansas teachers 📝 High school STEM educators recently completed our Professional Development Workshop, equipping them with cancer-focused biology lesson plans. The unit, Intro to Cancer: Leukemia & Hina’s Story, tells the story of an 11-year-old girl diagnosed with Acute Lymphocytic Leukemia. Students learn about the cell cycle, blood cell differentiation, the immune system and how cancer can disrupt these processes.
A group of seven people standing indoors, smiling at the camera. They are in a brightly lit room with a railing visible on the right side.

ALT A group of seven people standing indoors, smiling at the camera. They are in a brightly lit room with a railing visible on the right side.

2
1
5
207
KU Cancer Center retweeted
University Of Kansas Radiation Oncology@KURadonc
Jun 1
Ron Chen, MD, MPH, FASCO, FASTRO, KUMC Rad Onc Chair, presented "Health Related Quality of Life with Pembrolizumab, Results From The AMBASSADOR Randomized Trial (A031501)" at ASCO 2026 Annual Meeting. @RonaldChenMD @KUcancercenter @KUMedicine @ASCO
2
5
205
KU Cancer Center retweeted
Bret Freudenthal@Freudlab
Jun 1
That's a wrap on the 25th Annual Midwest DNA Repair Symposium at the University of Kansas Medical Center. Two days, 175 attendees, 4 keynotes, 22 talks, and 85 posters of genuinely incredible science (also some fun socializing of course). I am still smiling, but a bit tired. 🧬🌻
2
1
14
744
For #ASCO26 attendees: see “Early results of COMPARE, a prospective comparison of outcomes with proton and photon radiation in prostate cancer” as part of the Rapid Oral Abstract Session happening at 4:30pm in Hall D1.
Headshots of Dr. Aaron Katz and Dr. Ronald Chen appear next to text for a research presentation on “Early results of COMPARE, a prospective comparison of outcomes with proton and photon radiation in prostate cancer” happening at the ASCO annual meeting

ALT Headshots of Dr. Aaron Katz and Dr. Ronald Chen appear next to text for a research presentation on “Early results of COMPARE, a prospective comparison of outcomes with proton and photon radiation in prostate cancer” happening at the ASCO annual meeting
3
7
315
Also in this morning’s poster sessions, melanoma research involving Dr. Gary Doolittle is on display in Hall A at board 249. See “Circulating tumor DNA (ctDNA) clearance after immune checkpoint inhibition (ICI) with radiotherapy (RT) as a prognostic indicator for patients with advanced melanoma” from 9am-12pm.
Headshot of Dr. Gary Doolittle is next to text information on a research presentation regarding “Circulating tumor DNA (ctDNA) clearance after immune checkpoint inhibition (ICI) with radiotherapy (RT) as a prognostic indicator for patients with advanced melanoma” happening at the ASCO annual meeting

ALT Headshot of Dr. Gary Doolittle is next to text information on a research presentation regarding “Circulating tumor DNA (ctDNA) clearance after immune checkpoint inhibition (ICI) with radiotherapy (RT) as a prognostic indicator for patients with advanced melanoma” happening at the ASCO annual meeting
1
2
143
Happy Sunday #ASCO26! Dr. Xinglei Shen will be presenting this morning in Poster Hall A from 9am-12pm. Find him at board 118 to hear about “Image‑only and multimodal AI digital pathology biomarkers to demonstrate risk stratification across standard prostate cancer management strategies”
A headshot of Dr. Xinglei Shen is next to text information for his presentation on “Image‑only and multimodal AI digital pathology biomarkers to demonstrate risk stratification across standard prostate cancer management strategies” happening at the ASCO annual meeting

ALT A headshot of Dr. Xinglei Shen is next to text information for his presentation on “Image‑only and multimodal AI digital pathology biomarkers to demonstrate risk stratification across standard prostate cancer management strategies” happening at the ASCO annual meeting
1
2
110
Hello #ASCO26 attendees! Find @anup_kasi presenting during this afternoon’s Poster Sessions. From 1:30-4:30pm, he will be at board 149b in Poster Hall A presenting “A late‑phase randomized open‑label multi‑cohort trial to evaluate immune‑related adverse events with different standard‑of‑care dosing strategies of standard‑of‑care immunotherapies: ImmuRAD trial.” What a great team of multidisciplinary researchers represented in that study!
A graphic shows the headshots of ten people alongside info about their presentation on “A late‑phase randomized open‑label multi‑cohort trial to evaluate immune‑related adverse events with different standard‑of‑care dosing strategies of standard‑of‑care immunotherapies: ImmuRAD trial” happening at the ASCO annual meeting.

ALT A graphic shows the headshots of ten people alongside info about their presentation on “A late‑phase randomized open‑label multi‑cohort trial to evaluate immune‑related adverse events with different standard‑of‑care dosing strategies of standard‑of‑care immunotherapies: ImmuRAD trial” happening at the ASCO annual meeting.
1
177
If you’re attending #ASCO26: Head over to the Arie Crown Theater at 3:57pm where @RonaldChenMD is presenting “Health‑related quality of life (HRQOL) with pembrolizumab or observation for high‑risk muscle‑invasive urothelial carcinoma after surgery: Results from the AMBASSADOR randomized trial (Alliance A031501.)” The Oral Abstract Session starts at 2:45pm.
A graphic shows a headshots of Dr. Ron Chen smiling next to information related to his presentation of "Health‑related quality of life (HRQOL) with pembrolizumab or observation for high‑risk muscle‑invasive urothelial carcinoma after surgery: Results from the AMBASSADOR randomized trial (Alliance A031501.)" happening at the ASCO Annual Meeting

ALT A graphic shows a headshots of Dr. Ron Chen smiling next to information related to his presentation of "Health‑related quality of life (HRQOL) with pembrolizumab or observation for high‑risk muscle‑invasive urothelial carcinoma after surgery: Results from the AMBASSADOR randomized trial (Alliance A031501.)" happening at the ASCO Annual Meeting
1
5
201
Good morning #ASCO26! Later today, don’t miss Dr. Marc Hoffmann presenting “Golcadomide (GOLCA), a potential, first‑in‑class, oral CELMoD Pola‑RCHP in patients with newly diagnosed aggressive B‑cell lymphoma (a‑BCL): Safety and 12‑month efficacy results.” It’s part of the Rapid Oral Abstract session happening in Room E450a at 1pm.
A graphic shows a headshots of Dr. Marc Hoffmann smiling next to information related to his presentation of "Golcadomide (GOLCA), a potential, first‑in‑class, oral CELMoD Pola‑RCHP in patients with newly diagnosed aggressive B‑cell lymphoma (a‑BCL): Safety and 12‑month efficacy results" happening at the ASCO Annual Meeting

ALT A graphic shows a headshots of Dr. Marc Hoffmann smiling next to information related to his presentation of "Golcadomide (GOLCA), a potential, first‑in‑class, oral CELMoD Pola‑RCHP in patients with newly diagnosed aggressive B‑cell lymphoma (a‑BCL): Safety and 12‑month efficacy results" happening at the ASCO Annual Meeting
1
5
194
Hello #ASCO26! We are excited for this year’s annual meeting and encourage you to follow along using the official conference hashtag. Safe travels to Chicago!
1
117
Led by @KUcancercenter's Dr. Joseph McGuirk and published in @BloodPortfolio's Blood Advances: Allogeneic CD19 CAR T (CTX110) in relapsed/refractory B‑cell NHL showed 65% response and 39% complete response at higher doses, w/a manageable safety profile. ashpublications.org/bloodadv…

Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell...

Key Points. CTX110 showed acceptable safety and promising preliminary efficacy at higher dose levels in patients with relapsed/refractory B-cell NHL.Alloge

ashpublications.org
2
2
164
“This re-accreditation affirms the quality and impact of our training program…” — Dr. Babalola Faseru The University of Kansas Medical Center’s Tobacco Treatment Specialist Training Program is re-accredited through 2031, continuing efforts to reduce tobacco use and prevent cancer. Read more → kucancercenter.org/news-room…
2
143
Congratulations to the @UnivOfKansas faculty and researchers who received promotions and tenure, including our cancer center members! bit.ly/4tHlVwS

KU announces promotion and tenure for 146 faculty and researchers

Chancellor Douglas A. Girod has approved the promotion and award of tenure, where indicated, for 50 individuals at the University of Kansas Lawrence and Edwards campuses and 96 individuals at the KU...

news.ku.edu
1
2
184
"One message resonated clearly: cancer centers must continue to communicate with authenticity, empathy, agility, and measurable impact." We're proud to see Christine Thomas, JD, co-author the latest #AACICommentary alongside Meredith Rae Vehar, MPA. Thank you for sharing your reflections and insights from the recent NACCDO-CMCA conference in Toronto. Read their thoughts here → conta.cc/4u3ZjaI @AACI_Cancer
110
KU Cancer Center retweeted
NFL Alumni
@NFLAlumni
May 14
Thank you to all the cancer survivors and friends who joined @NFLAKC last weekend to share their experiences, discuss challenges, and foster connection with other men in the community. Moments like these remind us why it is important for all of us to reach out and take control of our health. Grateful to former KC Chiefs @JCPearson24, @WShields68, @CherryDeron, @dahughesguy83 and Tim Barnett who led the discussion! Are you in Pittsburgh or NY/NJ? Join us for listening sessions on May 30 and Jun 11 respectively. Register online at nflagearup.org/cancer #GearUpAgainstCancer
1:30
1
5
9
1,387
KU Cancer Center retweeted
Association of American Cancer Institutes@AACI_Cancer
May 15
Thank you @JerryMoran for speaking w/ @KUcancercenter Director @RoyJensenMD & Cancer Center Community Advisory Board Chair Jason Hale at AACI/@AACR #HillDay. We're grateful to share the value of cancer research in #Kansas. #FundNIH #FundNCI #AACIOnTheHill #UnitedByCancerResearch
1
3
209
Load more